Hinova Pharmaceuticals, Inc. Class ASSE: 688302

Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis